Table 4.
Summary of time-to-event outcome studies using competing risk analyses
| Cumulative incidences (post-SRS months) | HR (95 % CI) | p value | ||||
|---|---|---|---|---|---|---|
| 6 | 12 | 24 | 36 | |||
| Neurological death | 1.637 (1.174–2.281) | 0.0036 | ||||
| Asymptomatic (group A) | 0.021 | 0.033 | 0.057 | 0.068 | ||
| Symptomatic (group B) | 0.030 | 0.073 | 0.100 | 0.110 | ||
| Neurological deterioration | 1.425 (1.073–1.894) | 0.014 | ||||
| Asymptomatic (group A) | 0.032 | 0.057 | 0.080 | 0.096 | ||
| Symptomatic (group B) | 0.047 | 0.093 | 0.121 | 0.130 | ||
| Local recurrencea | 1.360 (0.926–1.998) | 0.11 | ||||
| Asymptomatic (group A) | 0.017 | 0.046 | 0.062 | 0.072 | ||
| Symptomatic (group B) | 0.023 | 0.057 | 0.091 | 0.099 | ||
| Repeat SRS | 0.880 (0.736–1.053) | 0.16 | ||||
| Asymptomatic (group A) | 0.153 | 0.256 | 0.301 | 0.318 | ||
| Symptomatic (group B) | 0.131 | 0.229 | 0.269 | 0.275 | ||
| SRS-related complications | 0.088 (0.514–1.507) | 0.64 | ||||
| Asymptomatic (group A) | 0.006 | 0.013 | 0.021 | 0.026 | ||
| Symptomatic (group B) | 0.012 | 0.021 | 0.027 | 0.027 | ||
SRS stereotactic radiosurgery, HR hazard ratio, CI confidence interval
aBased on 1165 [567 (69.0 %) in group A and 598 (72.8 %) in group B, p = 0.10] patients (479 patients were excluded because neuro-imaging results were not available)